Disability and pain after cortisone versus placebo injection for trapeziometacarpal arthrosis and de Quervain syndrome
Tóm tắt
This study tested the null hypothesis that type of injection (corticosteroid vs. placebo) is not a predictor of arm-specific disability as measured with the Disabilities of Arm, Shoulder and Hand questionnaire 1 to 3 months after injection of dexamethasone or placebo for treatment of trapeziometacarpal (TMC) arthrosis or de Quervain syndrome. Secondly, we tested if type of injection was a predictor of pain intensity. Thirty-six English-speaking adults with TMC arthrosis or de Quervain syndrome were randomized for a dexamethasone or a placebo injection. At time of the injection, patients completed a demographic data sheet and validated questionnaires assessing arm-specific disability, pain intensity, depressive symptoms, pain catastrophizing, and patient’s health-related beliefs. At an average of 1.4 ± 0.42 months (range, 0.79–2.5 months) after the injection, patients completed questionnaires regarding arm-specific disability, pain, and treatment satisfaction. Grip and pinch strength measurements were measured at both time points. Bivariable and multivariable analyses assessed predictors of arm-specific disability and pain intensity at follow-up. Type of injection was not a predictor of arm-specific disability or pain intensity 1 to 3 months after injection. The best model both for arm-specific disability and pain intensity at follow-up included pain catastrophizing and explained 18 % and 33 % of the variability, respectively. Catastrophic thinking was a better predictor of both of arm-specific disability and pain intensity than diagnosis or type of injection (steroid vs. placebo) 1to 3 months after an injection.
Tài liệu tham khảo
Bahadir C, Onal B, Dayan VY, et al. Comparison of therapeutic effects of sodium hyaluronate and corticosteroid injections on trapeziometacarpal joint osteoarthritis. Clin Rheumatol. 2009;28:529–33.
Calderon SA, Zurakowski D, Davis JS, et al. Quantitative adjustment of the influence of depression on the disabilities of the arm, shoulder, and hand (DASH) questionnaire. Hand (NY). 2010;5:49–55.
De SD, Vranceanu AM, Ring DC. Contribution of kinesiophobia and catastrophic thinking to upper-extremity-specific disability. J Bone Joint Surg Am. 2013;95:76–81.
Heyworth BE, Lee JH, Kim PD, et al. Hylan versus corticosteroid versus placebo for treatment of basal joint arthritis: a prospective, randomized, double-blinded clinical trial. J Hand Surg Am. 2008;33:40–8.
Hudak PL, Amadio PC, Bombardier C, The Upper Extremity Collaborative Group (UECG). Development of an upper extremity outcome measure: the DASH (disabilities of the arm, shoulder and hand) [corrected]. Am J Ind Med. 1996;29:602–8.
Jeyapalan K, Choudhary S. Ultrasound-guided injection of triamcinolone and bupivacaine in the management of De Quervain’s disease. Skeletal Radiol. 2009;38:1099–103.
Joshi R. Intraarticular corticosteroid injection for first carpometacarpal osteoarthritis. J Rheumatol. 2005;32:1305–6.
Khan M, Waseem M, Raza A, et al. Quantitative assessment of improvement with single corticosteroid injection in thumb CMC joint osteoarthritis? Open Orthop J. 2009;3:48–51.
Kovacs FM, Seco J, Royuela A, et al. The correlation between pain, catastrophizing, and disability in subacute and chronic low back pain: a study in the routine clinical practice of the Spanish National Health Service. Spine (Phila Pa 1976). 2011;36:339–45.
Maarse W, Watts AC, Bain GI. Medium-term outcome following intra-articular corticosteroid injection in first CMC joint arthritis using fluoroscopy. Hand Surg. 2009;14:99–104.
McDermott JD, Ilyas AM, Nazarian LN, et al. Ultrasound-guided injections for de Quervain’s tenosynovitis. Clin Orthop Relat Res. 2012;470:1925–31.
Meenagh GK, Patton J, Kynes C, et al. A randomised controlled trial of intra-articular corticosteroid injection of the carpometacarpal joint of the thumb in osteoarthritis. Ann Rheum Dis. 2004;63:1260–3.
Parr JJ, Borsa PA, Fillingim RB, et al. Pain-related fear and catastrophizing predict pain intensity and disability independently using an induced muscle injury model. J Pain. 2012;13:370–8.
Peters-Veluthamaningal C, Winters JC, Groenier KH, et al. Randomised controlled trial of local corticosteroid injections for de Quervain’s tenosynovitis in general practice. BMC Musculoskelet Disord. 2009;10:131.
Radloff LS. The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Meas. 1977;1:385–401.
Sawaizumi T, Nanno M, Ito H. De Quervain’s disease: efficacy of intra-sheath triamcinolone injection. Int Orthop. 2007;31:265–8.
Sullivan MJL, Pivik J. The pain catastrophizing scale: development and validation. Psychol Assess. 1995;7:524–32.
Vranceanu AM, Barsky A, Ring D. Psychosocial aspects of disabling musculoskeletal pain. J Bone Joint Surg Am. 2009;91:2014–8.
Vranceanu AM, Jupiter JB, Mudgal CS, et al. Predictors of pain intensity and disability after minor hand surgery. J Hand Surg Am. 2010;35:956–60.
Wallston KA, Wallston BS, DeVellis R. Development of the multidimensional health locus of control (MHLC) scales. Health Educ Monogr. 1978;6:160–70.
Weissman MM, Sholomskas D, Pottenger M, et al. Assessing depressive symptoms in five psychiatric populations: a validation study. Am J Epidemiol. 1977;106:203–14.
Wolf JM. Injections for trapeziometacarpal osteoarthrosis. J Hand Surg Am. 2010;35:1007–9.